Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMBS | P08397 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19976572 | 0.81 | HMBS (0.33) | HMBS | |
| SCHEMBL23467399 | 0.77 | — | — | |
| SCHEMBL21064210 | 0.74 | — | — | |
| SCHEMBL12792828 | 0.71 | HMBS (0.50) | HMBSKDM4EALDH1A1POLB | |
| SCHEMBL27453822 | 0.68 | ALDH1A1 (0.43) | ALDH1A1MAPTALOX15 | |
| SCHEMBL796518 | 0.68 | — | — | |
| SCHEMBL21064192 | 0.67 | — | — | |
| SCHEMBL21794797 | 0.65 | HMBS (0.48) | HMBSKDM4E | |
| SCHEMBL7445351 | 0.65 | — | — | |
| SCHEMBL10830318 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028051-B2 | Tetrahydroquinoline-based bromodomain inhibitors | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028051-B2 | Tetrahydroquinoline-based bromodomain inhibitors | BRDT, BRD4, BRD3 | HMBS 2575/4885KDM4E 1121/4885ALDH1A1 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.